共 50 条
- [35] Cost-Effectiveness Analysis of 177Lu-PSMA-617 Radioligand Therapy in Metastatic Castration-Resistant Prostate Cancer JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2023, 21 (01): : 43 - +
- [39] Re: Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer JOURNAL OF UROLOGY, 2022, 207 (02): : 467 - 468
- [40] 177Lu-PSMA-617 radioligand therapy and outcome in patients with metastasized castration-resistant prostate cancer European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44 : 1663 - 1670